4th-generation, 3 chamber IV nutrition receives reimb

Will face competitions

This year, HK inno.N and Fresenius Kabi launched their products covered by reimbursement

Last year, Baxter and JW Pharmaceutical secured listing…The products contain enhanced amino acids contents

JW Pharmaceutical’s fourth-generation 3 chamber nutrient fluid was officially launched in January.

 

Fourth-generation 3 chamber Total Parenteral Nutrition (TPN), with enhanced amino acids contents, are being introduced into the market.

 

Following the reimbursement listing of related products by Baxter and JW Pharmaceutical, HK inno.N and Fresenius Kabi have joined the competition.

 

Companies that competed previously in the third-generation market are now entering fourth-generation market.

 

The 3-chamber nutrient fluid is an IV infusion product that contains 3-chamber bags for amino acids, lipids, and sugars.

 

Recent fourth-generation products contain higher amino acid contents.

 

On April 1, HK inno.N’s 'Omapplusone Inj' was listed for reimbursement at KRW 50,246.

 

Last year, Olimel N12E Inj was listed as a third-generation product for reimbursement for the first time.

 

From October to November of last year, four doses of Olimel N12E Inj (650, 1000, 1500, 2000 mL) were launched with reimbursement coverage.

 

Its reimbursement ceiling prices are KRW 29,746 for the 650 mL product and KRW 55,202 for the 2000 mL product.

 

JW Pharmaceutical’s Winuf A Plus Inj and Winuf A Plus Peri Inj entered the market as well.

 

From November to December of last year, two Winuf A Plus Inj (1090, 1438 mL) products and two Winuf A Plus Peri Inj (1089, 1452 mL) products were listed for reimbursement.

 

The minimum price was set at KRW 40,197 for Winuf A Plus Inj (1090 mL), and the maximum price was set at KRW 45,679 for (1452 mL) This year, HK inno.N reimbursement listed their products in February and this month.

 

Seven products, including three Omapplusone Inj (986ml, 1477ml, 1970 mL) and four Omapplusone Peri Inj (724, 952, 1448, 1904 mL), were reimbursement listed.

 

The company’s approach seems to offer a wide range of doses than its competitors.

 

The minimum price was set at KRW 31,285 for Omapplusone Peri Inj (724 mL), and the maximum price was set at KRW 54,153 for Omapplusone Inj (1970 mL).

 

Last January, Fresenius Kabi, a foreign pharmaceutical company, secured a listing of Ntense EF Inj (1012 mL) at KRW 40,197.

 

It was reported that the company is currently in the process of pricing Ntense Inj.

 

These four pharmaceutical companies compete intensely in the third-generation nutrition fluids market.

 

In order of market share, JW Pharmaceutical, Fresenius Kabi, HK inno.N, and Baxter dominate the market, which is approximately KRW 150 billion.

 

As pharmaceutical companies release their fourth-generation products into the market, tough competition for securing a place in the market is anticipated.